Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 16/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 14/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17680043 | 0.95 | CYP17A1 (0.44) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL6114362 | 0.95 | CYP17A1 (0.44) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL12168978 | 0.95 | CYP17A1 (0.44) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL8737122 | 0.95 | CYP17A1 (0.44) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL12168985 | 0.94 | CYP17A1 (0.42) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL12169016 | 0.94 | CYP17A1 (0.42) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL12169020 | 0.94 | CYP17A1 (0.42) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL12098142 | 0.94 | CYP17A1 (0.42) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL12442771 | 0.92 | CYP17A1 (0.43) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 | |
| SCHEMBL6114410 | 0.92 | CYP11B1 (0.40) | CYP17A1CYP19A1CYP11B1CYP11B2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9755152-B2 | Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9755152-B2 | Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20150155496-A1 | COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO LTD (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150155496-A1 | COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO LTD (JP) | 2015-06-04 | — | — | US | disclosed |
| US-8927119-B2 | Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8927119-B2 | Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20120126220-A1 | COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120126220-A1 | COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150155496-A1 | COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE | SLCO2B1, PNPO, SLCO2A1 | CYP17A1 652/4885CYP19A1 334/4885CYP11B1 793/4885 |
| US-20120126220-A1 | COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE | SLCO2B1, PNPO, SLCO2A1 | CYP17A1 652/4885CYP19A1 334/4885CYP11B1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.